1. Home
  2. VERV
  3. VERV News

Latest Verve Therapeutics Inc. (VERV) News on May 10, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

7 days ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
VERV

Motley Fool

11 days ago

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Why Verve Therapeutics Zoomed 40% Higher This Week
VERV

Motley Fool

21 days ago

Why Verve Therapeutics Zoomed 40% Higher This Week

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
VERV

Zacks

23 days ago

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

VERV

MT Newswires

24 days ago

Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade

Why Verve Therapeutics Is Skyrocketing Today
VERV

Motley Fool

24 days ago

Why Verve Therapeutics Is Skyrocketing Today

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
VERV

Zacks

24 days ago

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

VERV

MT Newswires

25 days ago

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks
VERV

Simply Wall St.

25 days ago

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
VERV

Pharmaceutical Technology

25 days ago

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.
VERV

Barrons.com

25 days ago

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

VERV

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

VERV

MT Newswires

a month ago

Top Premarket Gainers

VERV

MT Newswires

a month ago

Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial

Verve’s second swing at gene editing for heart disease shows early promise
VERV

BioPharma Dive

a month ago

Verve’s second swing at gene editing for heart disease shows early promise

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
VERV

GlobeNewswire

a month ago

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

VERV

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Premarket Friday

VERV

MT Newswires

a month ago

Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
VERV

GlobeNewswire

a month ago

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

a month ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector
VERV

TipRanks

a month ago

Biotech stocks slide as Marks resignation seen being negative for sector

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?
VERV

Insider Monkey

a month ago

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
VERV

GlobeNewswire

a month ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve gets FDA green light to expand base editing trial into US
VERV

BioPharma Dive

2 months ago

Verve gets FDA green light to expand base editing trial into US

VERV

MT Newswires

2 months ago

Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
VERV

GlobeNewswire

2 months ago

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

VERV

MT Newswires

2 months ago

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

2 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations
VERV

Simply Wall St.

2 months ago

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
VERV

Zacks

2 months ago

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

VERV

Associated Press Finance

2 months ago

Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
VERV

GlobeNewswire

2 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Vertex ends gene editing research pact with Verve
VERV

BioPharma Dive

2 months ago

Vertex ends gene editing research pact with Verve

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

3 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
VERV

GlobeNewswire

3 months ago

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
VERV

Simply Wall St.

3 months ago

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
VERV

Zacks

4 months ago

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
VERV

GlobeNewswire

4 months ago

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VERV

GlobeNewswire

4 months ago

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

4 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?
VERV

Insider Monkey

4 months ago

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?
VERV

Insider Monkey

4 months ago

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
VERV

Simply Wall St.

5 months ago

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

5 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV

MT Newswires

6 months ago

RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations
VERV

Simply Wall St.

6 months ago

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
VERV

Zacks

6 months ago

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates

VERV

Associated Press Finance

6 months ago

Verve Therapeutics: Q3 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
VERV

GlobeNewswire

6 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

6 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

State Street Corp's Strategic Acquisition in Verve Therapeutics
VERV

GuruFocus.com

7 months ago

State Street Corp's Strategic Acquisition in Verve Therapeutics

Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
VERV

Insider Monkey

7 months ago

Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?

Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’
VERV

Insider Monkey

8 months ago

Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’

Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc
VERV

GuruFocus.com

8 months ago

Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc

Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers
VERV

Insider Monkey

8 months ago

Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

8 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV

MT Newswires

9 months ago

RBC Capital Adjusts Price Target on Verve Therapeutics to $20 From $25, Maintains Outperform Rating

Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
VERV

Zacks

9 months ago

Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates

VERV

Associated Press Finance

9 months ago

Verve Therapeutics: Q2 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
VERV

GlobeNewswire

9 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

9 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
VERV

Simply Wall St.

9 months ago

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

VERV

MT Newswires

10 months ago

RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?
VERV

Insider Monkey

10 months ago

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

10 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
VERV

GlobeNewswire

10 months ago

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
VERV

Simply Wall St.

a year ago

One Verve Therapeutics Insider Raised Stake By 29% In Previous Year

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV

MT Newswires

a year ago

Verve Therapeutics Names Troy Lister Chief Scientific Officer

Verve Therapeutics Announces Leadership Update
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Leadership Update

Verve Therapeutics to Participate in Upcoming Investor Conferences
VERV

GlobeNewswire

a year ago

Verve Therapeutics to Participate in Upcoming Investor Conferences

VERV

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 05/16/2024

Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
VERV

Simply Wall St.

a year ago

Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
VERV

Simply Wall St.

a year ago

Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week

Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations
VERV

Simply Wall St.

a year ago

Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
VERV

Zacks

a year ago

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

VERV

Associated Press Finance

a year ago

Verve Therapeutics: Q1 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

Verve moves forward with backup base editing therapy
VERV

BioPharma Dive

a year ago

Verve moves forward with backup base editing therapy

Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
VERV

Zacks

a year ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

After a Serious Setback, Is Verve Therapeutics a Buy?
VERV

Motley Fool

a year ago

After a Serious Setback, Is Verve Therapeutics a Buy?

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
VERV

Zacks

a year ago

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
VERV

Zacks

a year ago

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
VERV

Investor's Business Daily

a year ago

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects

Verve Falls as Gene-Editing Trial Paused on Safety Issues
VERV

Bloomberg

a year ago

Verve Falls as Gene-Editing Trial Paused on Safety Issues

Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
VERV

Investor's Business Daily

a year ago

Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects

VERV

Reuters

a year ago

UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

VERV

Reuters

a year ago

Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

Verve Therapeutics Announces Updates on its PCSK9 Program
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Updates on its PCSK9 Program

Verve pauses base editing trial, shifts strategy after treatment side effect
VERV

BioPharma Dive

a year ago

Verve pauses base editing trial, shifts strategy after treatment side effect

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)
VERV

Simply Wall St.

a year ago

New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)

Verve Therapeutics Full Year 2023 Earnings: Beats Expectations
VERV

Simply Wall St.

a year ago

Verve Therapeutics Full Year 2023 Earnings: Beats Expectations

VERV

GuruFocus.com

a year ago

Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023

VERV

Associated Press Finance

a year ago

Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
VERV

GlobeNewswire

a year ago

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
VERV

InvestorPlace

a year ago

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

Share on Social Networks: